VBI Vaccines (VBIV)
(Delayed Data from NSDQ)
$0.09 USD
-0.02 (-18.97%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $0.08 -0.01 (-14.89%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for VBI Vaccines, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 24 | 63 | 122 | 119 | 44 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 9 | 7 | 3 | 2 | 1 |
Other Current Assets | 4 | 8 | 6 | 11 | 1 |
Total Current Assets | 36 | 78 | 130 | 132 | 47 |
Net Property & Equipment | 10 | 12 | 11 | 11 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 38 | 60 | 64 | 64 | 63 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 87 | 155 | 210 | 209 | 122 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 13 | 4 | 4 | 1 |
Current Portion Long-Term Debt | 51 | 0 | 0 | 0 | 15 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 18 | 23 | 27 | 13 | 13 |
Total Current Liabilities | 76 | 37 | 33 | 17 | 30 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 2 | 2 | 3 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 49 | 28 | 16 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 79 | 91 | 66 | 38 | 34 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 454 | 442 | 442 | 404 | 285 |
Capital Surplus | 107 | 90 | 82 | 76 | 66 |
Retained Earnings | -582 | -490 | -378 | -309 | -262 |
Other Equity | 28 | 21 | -2 | 1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 8 | 64 | 144 | 172 | 88 |
Total Liabilities & Shareholder's Equity | 87 | 155 | 210 | 209 | 122 |
Total Common Equity | 8 | 64 | 144 | 172 | 88 |
Shares Outstanding | 23.60 | 8.60 | 8.60 | 8.20 | 5.90 |
Book Value Per Share | 0.32 | 7.46 | 16.73 | 20.94 | 14.96 |
Fiscal Year End for VBI Vaccines, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 13 | 24 | 35 | 21 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 10 | 9 | 8 | 7 |
Other Current Assets | NA | 4 | 4 | 7 | 4 |
Total Current Assets | NA | 26 | 36 | 50 | 32 |
Net Property & Equipment | NA | 9 | 10 | 9 | 10 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 37 | 38 | 38 | 43 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 75 | 87 | 101 | 88 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 9 | 6 | 7 | 7 |
Current Portion Long-Term Debt | NA | 49 | 51 | 50 | 2 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 19 | 18 | 19 | 17 |
Total Current Liabilities | NA | 78 | 76 | 77 | 28 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 2 | 2 | 2 | 2 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 48 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 81 | 79 | 81 | 80 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 455 | 454 | 454 | 442 |
Capital Surplus | NA | 108 | 107 | 106 | 94 |
Retained Earnings | NA | -600 | -582 | -582 | -562 |
Other Equity | NA | 32 | 28 | 42 | 35 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -5 | 8 | 20 | 9 |
Total Liabilities & Shareholder's Equity | NA | 75 | 87 | 101 | 88 |
Total Common Equity | 0 | -5 | 8 | 20 | 9 |
Shares Outstanding | 28.60 | 28.60 | 23.60 | 23.30 | 22.80 |
Book Value Per Share | 0.00 | -0.19 | 0.32 | 0.85 | 0.38 |